Immunome Inc [IMNM] stock is trading at $14.62, up 1.67%. An important factor to consider is whether the stock is rising or falling in short-term value. The IMNM shares have gain 4.43% over the last week, with a monthly amount drifted -4.07%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on May 31, 2024, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $27. Previously, JP Morgan started tracking the stock with Overweight rating on April 30, 2024, and set its price target to $24. On April 15, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $35 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $30 on January 29, 2024. Wedbush initiated its recommendation with a Outperform and recommended $12 as its price target on December 19, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on October 29, 2021, and assigned it a price target of $35.
Immunome Inc [IMNM] stock has fluctuated between $6.93 and $30.96 over the past year. Currently, Wall Street analysts expect the stock to reach $30.33 within the next 12 months. Immunome Inc [NASDAQ: IMNM] shares were valued at $14.62 at the most recent close of the market. An investor can expect a potential return of 107.46% based on the average IMNM price forecast.
Analyzing the IMNM fundamentals
Immunome Inc [NASDAQ:IMNM] reported sales of 10.78M for the trailing twelve months, which represents a drop of -44.55%. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -25.18%, Pretax Profit Margin comes in at -24.35%, and Net Profit Margin reading is -24.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.89, Equity is -1.58 and Total Capital is -1.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.34 points at the first support level, and at 14.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.87, and for the 2nd resistance point, it is at 15.11.
Ratios To Look Out For
For context, Immunome Inc’s Current Ratio is 7.12. On the other hand, the Quick Ratio is 7.12, and the Cash Ratio is 4.14. Considering the valuation of this stock, the price to sales ratio is 81.44, the price to book ratio is 3.46.
Transactions by insiders
Recent insider trading involved Rosett Max, Chief Financial Officer, that happened on Sep 19 ’24 when 14380.0 shares were sold. Officer, Rosett Max completed a deal on Sep 19 ’24 to buy 14380.0 shares. Meanwhile, Director BIENAIME JEAN JACQUES bought 7000.0 shares on Aug 16 ’24.
